Revolutionary Dosing Schedule: Eli Lilly's Alzheimer's Drug Shows Promise

Eli Lilly's Alzheimer's drug Kisunla, under late-stage trials, shows promising interim results with a gradual dosing schedule, reducing serious brain swelling cases. The trial, which is under review by global health regulators, highlights a potential change in treatment strategy for early-stage Alzheimer's patients.

In a groundbreaking revelation, interim results from a late-stage trial indicate Eli Lilly's Alzheimer's drug, Kisunla, may offer a safer treatment schedule. The new gradual dosing schedule reportedly lessens the occurrence of serious brain swelling, a concern with amyloid-lowering drugs.

At a crucial 24-week milestone in the year-long study, 14% of patients on a lower starting dose experienced brain swelling known as ARIA-E, compared to 24% on the standard dosing. Notably, the amyloid plaque reduction was consistent across both dosing methods.

Set against the backdrop of competing drugs and regulatory scrutiny, Kisunla, also known as donanemab, is under review in the EU. Lilly aims to alter its dosing regimen for safer application, aspiring for broader acceptance and access across global healthcare landscapes.